Member of the International College of Neuropsychopharmacology
Member of the Asian Pacific Society for Neurochemistry/International Society for Neurochemistry
「永信李天德醫藥基金會得獎人聯誼會」會員
論文及期刊發表
Early Prediction of Clinical Response in Schizophrenia Patients Receiving Atypical Antipsychotic Zotepine. Journal of Clinical Psychiatry. 2007 Oct; 68(10):1522-7. Lin CH, Chou LS, Lin CH, Hsu CY, Chen YS, Lane HY*
Factors affecting time to rehospitalization for patients with major depressive disorder. Psychiatry and Clinical Neurosciences. 2007 Jun; 61(3):249-54. Lin CH*, Chen YS, Lin CH, Lin KS
Factors affecting time to rehospitalization for Chinese schizophrenic patients in Taiwan. The Kaohsiung Journal of Medical Sciences 2008 Aug; 24:408–14. Lin CH, Chen CC, Wang SY, Lin SC, Chen MC, Lin CH*
Factors predicting transferal after psychiatric emergency management in the elderly. Psychiatry and Clinical Neurosciences. 2009 Dec; 63(6):741-6. Lin CH, Hsu CW, Teng CY, Sun PC, Hsu HC, Wung YT, Lin CH*
Mirtazapine-associated Hair Loss. Journal of Clinical Psychiatry. 2010 Oct;71(10):1400-1 Lin CH, Hsu CW, Lin CH, Lane HY*
Time to rehospitalization in patients with major depression vs. those with schizophrenia or bipolar I disorder in a public psychiatric hospital. Psychiatry Research. 2010 Dec 30;180(2-3):74-9 Lin CH, Chen MC, Chou LS, Lin CH, Chen CC, Lane HY*
Glutamate signaling in the pathophysiology and therapy of schizophrenia. Pharmacology, Biochemestry and Behavior. 2012 Feb; 100(4):665-77. (Invited review) Lin CH, Lane HY, Tsai G*
Clozapine Protects Bone Mineral Density in Female Patients with Schizophrenia. International Journal of Neuropsychopharmacology. 2012;15:897-906. Lin CH, Huang KH, Chang YC, Huang YC, Hsu WC, Lin CY, Chou HC, Tsai G, Lane HY*
Optimizing the early prediction model for symptomatic remission with acute treatment for schizophrenia. Journal of Clinical Psychopharmacology. 2012; 32: 773-777. Lin CH, Chou LS, Lin CH, Hsu CY, Chen CC, Lane HY*
NMDA Neurotransmission Dysfunction in Behavioral and Psychological Symptoms of Alzheimer’s Disease. Current Neuropharmacology 2012; 10(3): 272-85. (Invited review) Huang YJ, Lin CH, Lane HY, Tsai G*
Potential Blood Biomarker for Disease Severity in the Taiwanese Population with Alzheimer’s disease. American Journal of Alzheimer's Disease and Other Dementias. 2013; 28(1): 75-83. Huang CW, Wang SJ, Wu SJ, Yang CC, Huang MW, Lin CH, Cheng HJ*
Clinical symptoms, mainly negative symptoms, mediate the influence of neurocognition and social cognition on functional outcome of schizophrenia. Schizophrenia Research. 2013 May; 146(1-3): 231-7. Lin CH, Huang CL, Chang YC, Chen PW, Lin CY, Tsai G, Lane HY*
Synergistic Effects of COMT and TPH2 on Social Cognition. Psychiatry. 2013; 76(3):273-294. Lin CH, Huang KH, Chang YC, Tsai G, Lane HY*
Benzoate, a D-Amino Acid Oxidase Inhibitor, for the Treatment of Early-Phase Alzheimer’s Disease: A Randomized, Double-Blind, Placebo-Controlled Trial. Biological Psychiatry. 2014 May 1; 75(9):678-85. Lin CH, Chen PK, Chang YC, Chou LJ, Chen YS, Tsai G, Lane HY*
Distinctively higher plasma G72 protein levels in patients with schizophrenia than in healthy individuals. Molecular Psychiatry. 2014 Jun; 19(6):636-637. Lin CH, Chang HT, Chen YJ, Lin CH, Huang CH, Tun R, Tsai G, Lane HY*
NMDA neurotransmission dysfunction in mild cognitive impairment and Alzheimer’s disease. Current Pharmaceutical Design. 2014 Oct; 20(32):5169-5179. (Invited review) Lin CH, Huang YJ, Lin CJ, Lane HY, Tsai G*
Sex-specific factors for bone density in patients with schizophrenia. International Clinical Psychopharmacology. 2015 Mar; 30(2):96-102. Lin CH, Lin CY, Huang TL, Wang HS, Chang YC, Lane HY*
Donepezil improved cognitive deficits in a patient with neurosyphilis. Clinical Neuropharmacology. 2015 Jul-Aug; 38(4):156-7. Wu YS, Lane HY, Lin CH*
Decreased mRNA expression for the two subunits of system xc- , SLC3A2 and SLC7A11, in WBC in patients with schizophrenia: evidence in support of the hypo-glutamatergic hypothesis of schizophrenia. Journal of Psychiatric Research. 2016 Jan; 72:58-63. Lin CH, Lin PP, Lin CY, Lin CH, Huang CH, Huang YJ, Lane HY*
Mania following ketamine abuse. Neuropsychiatric Disease and Treatment. 2016 Jan;12:237-239. Lu YY, Lin CH, Lane HY*
Spontaneous remission of ketamine-withdrawal related depression. Clinical Neuropharmacology. 2016 Jan-Feb;39(1):51-2. Lin PC, Lane HY, Lin CH*
Hypothyroidism may exacerbate valproate-related hyperammonemic delirium. Biomedicine (Taipei). 2016 Jun;6(2):31-32. Hung CC, Lin CH, Lane HY*
Effects of antipsychotics on bone mineral density in patients with schizophrenia: Gender differences. Clinical Psychopharmacology and Neuroscience. 2016 Aug;14(3):238-249. (Invited review) Chen CY, Lane HY, Lin CH*
Venous thromboembolism following dantrolene treatment for neuroleptic malignant syndrome. Clinical Psychopharmacology and Neuroscience. 2016 Nov;14(4):399-401. Chen PH, Lane HY, Lin CH*
β-hydroxybutyrate, pyruvate and metabolic profiles in patients with schizophrenia: A case control study. Psychoneuroendocrinology. 2016 Nov;73:1-8. Huang YC, Lin PY, Lee Y, Wu CC, Hsu ST, Hung CF, Chen CC, Chong MY, Lin CH, Wang LJ
Brexpiprazole for the treatment of schizophrenia. Expert Opinion On Pharmacotherapy. 2017 Feb; 18(2):217-223. (Invited review) Hsu WY, Lane HY, Lin CH*
New treatment strategies of depression: Based on mechanisms related to neuroplasticity. Neural Plasticity 2017 Apr;2017:4605971. doi: 10.1155/2017/4605971. (Invited review) Huang YJ, Lane HY, Lin CH*
PICK1 genetic variation and cognitive function in patients with schizophrenia. Scientific Reports 2017 May 15;7(1):1889. doi: 10.1038/s41598-017-01975-y. Chen YT, Lin CH, Huang CH, Liang WM, Lane HY*
Gender differences in susceptibility to schizophrenia: potential implication of neurosteroids. Psychoneuroendocrinology 2017 Oct;84:87-93. Huang YC, Hung CF, Lin PY, Lee Y, Wu CC, Hsu ST, Chen CC, Chong MY, Lin CH, Wang LJ
Bupropion interferes with the image diagnosis of Parkinson disease. Neuropsychiatric Disease and Treatment 2017 Oct 19;13:2637-2639. Lin CH, Lane HY*
Blood levels of D-amino acid oxidase vs. D-amino acids in reflecting cognitive aging. Scientific Reports 2017 Nov 1. 7:14849. Lin CH, Yang HT, Chiu CC, Lane HY*
Genetic biomarkers on cognitive aging. Frontiers in Psychiatry 2017 Nov;8:247. Lin CH, Lin Eugene, Lane HY*
Increased serum levels of cysteine in patients with schizophrenia: A potential marker of cognitive function preservation. Schizophrenia Research 2018 Feb;192:391-397. Wang LJ, Lin PY, Lee Y, Huang YC, Wu CC, Hsu ST, Chen CC, Chong MY, Lin CH, Hung CF*
Medications used for cognitive enhancement in patients with schizophrenia, bipolar Disorder, Alzheimer’s disease, and Parkinson’s disease. Frontiers in Psychiatry 2018 Apr 4;9:91. Hsu WY, Lane HY, Lin CH*
Brain stimulation in Alzheimer’s disease. Frontiers in Psychiatry 2018 May 22;9:201. Chang CH, Lane HY, Lin CH*
Sodium benzoate, a D-amino acid oxidase inhibitor, added to clozapine for the treatment of schizophrenia: a randomized, double-Blind, placebo-controlled trial. Biological Psychiatry 2018 Sep 15;84(6):422-432. Lin CH, Lin CH, Chang YC, Huang YJ, Chen PW, Lane HY*
Combination of G72 genetic variation and G72 protein level to detect schizophrenia: Machine learning approaches. (#Equal contribution) Frontiers in Psychiatry 2018 Nov 6;9:566. Lin Eugene#, Lin CH#, Lai YL, Huang CH, Huang YJ, Lane HY*
Altered mRNA expressions for N-methyl-D-aspartate receptor-related genes in WBC of patients with major depressive disorder. Journal of Affective Disorder 2019 Feb;245:1119-1125. Lin CH, Huang MW, Lin CH, Huang CH, Lane HY*
Early identification and intervention of schizophrenia: insight from hypotheses of glutamate dysfunction and oxidative stress. Frontiers in Psychiatry 2019 Feb 27;10:93. Lin CH, Lane HY*
Long-term Use of Clozapine is Protective for Bone Density in Patients with Schizophrenia. Scientific Reports 2019 Mar 7;9(1):3895. Lin CH, Lin CY, Wang HS, Lane HY*
Effects of donepezil on cognition and global functioning in patients with delayed encephalopathy after carbon monoxide poisoning – A case series. Psychiatry and Clinical Neurosciences 2019 Jun;73(6):348. Tseng WT, Yeh JY, Lane HY, Lin CH*
Effect of N-methyl-D-aspartate-receptor-enhancing agents on cognition in patients with schizophrenia: A systematic review and meta-analysis of double-blind randomised controlled trials. Journal of Psychopharmacology 2019 Apr;33(4):436-448. Chang CH, Lane HY, Tseng PT, Chen SJ, Liu CY, Lin CH*
The Role of N-methyl-D-aspartate Receptor Neurotransmission and Precision Medicine in Behavioral and Psychological Symptoms of Dementia. Frontiers in Pharmacology 2019 May 22;10:540. Lin CH, Lane HY*
Sodium Benzoate for the Treatment of Behavioral and Psychological Symptoms of Dementia (BPSD): a Randomized, Double-blind, Placebo-controlled, 6-week Trial. Journal of Psychopharmacology 2019 Aug;33(8):1030-1033. Lin CH, Yang HT, Chen PK, Wang SH, Lane HY*
pLG72 levels increase in early phase of Alzheimer's disease but decrease in late phase Scientific Reports 2019 Sep 13;9(1):13221. Lin CH, Chiu CC, Huang CH, Yang HT, Lane HY*
D-glutamate, D-serine, and D-alanine differ in their roles in cognitive decline in patients with Alzheimer’s disease or mild cognitive impairment. Pharmacology, Biochemistry and Behavior 2019 Oct;185:172760. Lin CH, Yang HT, Lane HY*
C-Reactive Protein is Associated With Severity of Thought and Language Dysfunction in Patients With Schizophrenia. Neuropsychiatric Disease and Treatment 2019 Sep 10;15:2621-2627. Chang CH, Lane HY*, Liu CY, Cheng PC, Chen SJ, Lin CH*
Paliperidone is associated with reduced risk of severe hepatic outcome in patients with schizophrenia and viral hepatitis: A nationwide population-based cohort study. Psychiatry Research 2019 Oct 2;281:112597. Chang CH, Lane HY*, Liu CY, Chen SJ, Lin CH*
Novel Treatment for the hardest-to-treat Schizophrenia: Dual Activation of NMDA Receptor and Antioxidant. Current Drug Targets 2020;21(6):610-615. Lin CH, Chen YM, Lane HY*
Editorial: Glutamate-related biomarkers for neuropsychiatric disorders. Frontiers in Psychiatry 2019 Dec 5;10:904. Lin CH, Hashimoto K, Lane HY*
Polymorphism in the LASP1 gene promoter region alters cognitive functions of patients with schizophrenia. (#Equal contribution) Scientific Reports 2019 Dec 11;9:18840. Lin CH#, Yang Sheng#, Huang YJ, Lane HY*
The Role of N-methyl-D-aspartate Receptor on Late-Life Depression. International Journal of Gerontology 2019 Dec;13(4):268-272. (Invited review) Hsieh MT, Lane HY, Lin CH*
Survey of NMDA receptor-related biomarkers for depression. Current Pharmaceutical Design 2020;26(2):228-235. Chen YM, Lin CH*, Lane HY*
Precision Psychiatry Applications with Pharmacogenomics: Artificial Intelligence and Machine Learning Approaches. International Journal of Molecular Sciences 2020 Feb 1;21(3):969. Lin Eugene, Lin CH*, Lane HY*
Precision Medicine of Sodium Benzoate for the Treatment of Behavioral and Psychological Symptoms of Dementia (BPSD). Neuropsychiatric Disease and Treatment 2020 Feb 20;16:509-518. Lin CH, Yang HT, Chen PK, Wang SH, Lane HY*
Genetic Effects of DISC1 and G72 (DAOA) on Visual Learning of Patients with Schizophrenia. (#Equal contribution) Neuropsychiatric Disease and Treatment 2020 Mar 20;16:771-780. Chang Jane#, Huang KH#, Lin CH*, Lane HY*
Efficacy and cognitive effect of sarcosine (N-methylglycine) in patients with schizophrenia: a systematic review and meta-analysis of double-blind randomised controlled trials. (#Equal contribution) Journal of Psychopharmacology 2020 May;34(5):495-505. Chang CH#, Lin CH#, Liu CY, Chen SJ, Lane HY*
D-Glutamate and gut microbiota in Alzheimer’s disease. International Journal of Molecular Sciences 2020 Apr 11;21(8):2676. Chang CH, Lin CH*, Lane HY*
An ensemble approach to predict schizophrenia using protein data in the N-methyl-D-aspartate receptor (NMDAR) and tryptophan catabolic pathways. Frontiers in Bioengineering and Biotechnology 2020 Jun 4;8:569. Lin Eugene, Lin CH*, Hung CC, Lane HY*
Relevant Applications of Generative Adversarial Networks in Drug Design and Discovery: Molecular De Novo Design, Dimensionality Reduction, and De Novo Peptide and Protein Design. Molecules 2020 Jul 16;25(14):3250. Lin Eugene, Lin CH*, Lane HY*
D2 dopamine receptor gene (DRD2) Taq1A (rs1800497) affects bone density. Scientific Reports 2020 Aug 6;10(1):13236. Chiang TI, Lane HY, Lin CH*
Trough melatonin levels differ between early and late phases of Alzheimer disease. Clinical Psychopharmacology and Neuroscience 2021 Feb 28;19(1):135-144. Lin CH, Chiu CC, Lane HY*
Involvement of Cholinergic, Adrenergic, and Glutamatergic Network Modulation with Cognitive Dysfunction in Alzheimer’s Disease. International Journal of Molecular Sciences 2021 Feb 25;22(5):2283. Cheng YJ, Lin CH*, Lane HY*
Plasma D-glutamate levels for detecting mild cognitive impairment and Alzheimer’s disease: Machine learning approaches. (#Equal contribution) Journal of Psychopharmacology 2021 Mar;35(3):265-272. Chang CH#, Lin CH#, Liu CY, Huang CS, Chen SJ, Lin WC, Yang HT, Lane HY*:
Machine learning and novel biomarkers for the diagnosis of Alzheimer’s disease. International Journal of Molecular Sciences 2021 Mar 9;22(5):2761. Chang CH, Lin CH*, Lane HY*
Applying a bagging ensemble machine learning approach to predict functional outcome of schizophrenia with clinical symptoms and cognitive functions. Scientific Reports 2021 Mar 25;11(1):6922. Lin Eugene, Lin CH*, Lane HY*
Effect of Sodium Benzoate on Cognitive Function Among Patients With Behavioral and Psychological Symptoms of Dementia: Secondary Analysis of a Randomized Clinical Trial. JAMA Network Open 2021 Apr 1;4(4):e216156. Lin CH, Chen PK, Wang SH, Lane HY*
Prediction of Functional Outcomes of Schizophrenia with Genetic Biomarkers Using a Bagging Ensemble Machine Learning Method with Feature Selection. Scientific Reports 2021 May 13;11(1):10179. Lin Eugene, Lin CH*, Lane HY*
Reply: Trough melatonin levels have no physiological or clinical relevance. Clinical Psychopharmacology and Neuroscience 2021 May 31;19(2):393. Lin CH, Lane HY*
Brain activity of benzoate, a D-amino acid oxidase inhibitor, in patients with mild cognitive impairment in a randomized, double-blind, placebo controlled clinical trial. International Journal of Neuropsychopharmacology 2021 May 18;24(5):392-399. Lane HY, Tu CH, Lin WC, Lin CH*
Molecular Basis of Late-Life Depression. International Journal of Molecular Sciences 2021 Jul 10;22(14):7421. Kuo CY, Lin CH*, Lane HY*
Novel Biomarkers of Alzheimer’s Disease: Based upon NMDAR Hypoactivation and Oxidative Stress. Clinical Psychopharmacology and Neuroscience 2021 Aug 31;19(3):423-433. Chiang TI, Yu YH, Lin CH*, Lane HY*
Characterization of Potential Protein Biomarkers for Major Depressive Disorder Using Matrix-Assisted Laser Desorption Ionization/Time-of-Flight Mass Spectrometry (#Equal contribution). Molecules 2021 Jul 23;26(15):4457. Lin CH#, Su H#, Hung CH, Lane HY*, Shiea J*
Deep Learning with Neuroimaging and Genomics in Alzheimer's Disease. International Journal of Molecular Sciences 2021 Jul 24;22(15):7911. Lin Eugene, Lin CH*, Lane HY*
Novel therapeutic approaches for Alzheimer’s disease: an updated review. International Journal of Molecular Sciences 2021 Jul 30;22(15):8208. Yu TW, Lane HY*, Lin CH*
The relationships between hyperprolactinemia, metabolic disturbance, and sexual dysfunction in patients with schizophrenia under olanzapine treatment (#Equal contribution). Frontiers in Pharmacology 2021 Aug 5;12:718800. Wu TH#, Lin CH#, Goh KK, Chen YA, Chen CH, Lane HY, Lu ML
From menopause to neurodegeneration - molecular basis and potential therapy. International Journal of Molecular Sciences 2021 Aug 11;22(16):8654. Cheng YJ, Lin CH*, Lane HY*
Cystine/Glutamate Antiporter in Schizophrenia: From Molecular Mechanism to Novel Biomarker and Treatment. International Journal of Molecular Sciences 2021 Sep 8;22(18):9718. Hung CC, Lin CH*, Lane HY*
D-Amino Acids and pLG72 in Alzheimer’s Disease and Schizophrenia. International Journal of Molecular Sciences 2021 Oct 9;22(20):10917. Cheng YJ, Lin CH*, Lane HY*
Machine Learning and Deep Learning for the Pharmacogenomics of Antidepressant Treatments. Clinical Psychopharmacology and Neuroscience 2021 Nov 30;19(4):577-588. Lin Eugene, Lin CH*, Lane HY*
Plasma glutathione levels decreased with cognitive decline among people with mild cognitive impairment (MCI): a two-year prospective study. Antioxidants 2021 Nov 19;10(11):1839. Lin CH, Lane HY*
Logistic ridge regression to predict bipolar disorder using mRNA expression levels in the N-methyl-D-aspartate receptor genes. Journal of Affective Disorders 2022 Jan 15;297:309-313. Lin Eugene, Lin CH*, Lane HY*
Distinctively lower DISC1 mRNA levels in patients with schizophrenia, especially in those with higher positive, negative, and depressive symptoms. Pharmacology, Biochemistry and Behavior 2022 Feb;213:173335. Chen YM, Lin CH*, Lane HY*
Effects of sodium benzoate, a D-amino acid oxidase inhibitor, on perceived stress and cognitive function among patients with late-life depression: A randomized, double-blind, sertraline- and placebo-controlled trial. International Journal of Neuropsychopharmacology 2022 Aug 4;25(7):545-555. Lin CH, Wang SH, Lane HY*
A bagging ensemble machine learning framework to predict overall cognitive function of schizophrenia patients with cognitive domains and tests. Asian Journal of Psychiatry 2022 Mar;69:103008. Lin Eugene, Lin CH*, Lane HY*
De Novo Peptide and Protein Design Using Generative Adversarial Networks: An Update. Journal of Chemical Information and Modeling 2022 Feb 28;62(4):761-774. Lin Eugene, Lin CH*, Lane HY*
Suicide ideation among outpatients with alcohol use disorder. Behavioural Neurology 2022 Feb 12;2022:4138629. Hsu WY, Lin CH*, Lane HY*
Blood D-amino acid oxidase (DAO) levels increased with cognitive decline among people with mild cognitive impairment (MCI): a two-year prospective study. International Journal of Neuropsychopharmacology 2022 Aug 16;25(8):660-665. Lin CH, Lane HY*
Diagnosing Alzheimer’s disease specifically and sensitively with pLG72 and cystine/glutamate antiporter SLC7A11 as blood biomarkers. International Journal of Neuropsychopharmacology 2022 Aug 20:pyac053. Lane HY, Lin CH*
Targeting D-Amino Acid Oxidase (DAAO) for the Treatment of Schizophrenia: Rationale and Current Status of Research. CNS Drugs 2022 Nov;36(11):1143-1153. Kuo CY, Lin CH*, Lane HY*
Endogenous Antioxidants Predicted Outcome and Increased after Treatment: a Benzoate Dose-finding, Randomized, Double-blind, Placebo-controlled Trial for Alzheimer's Disease. Psychiatry and Clinical Neurosciences 2022 Nov 6. doi: 10.1111/pcn.13504. Online ahead of print. Lane HY, Wang SH, Lin CH*
Ketamine, benzoate, and sarcosine for treating depression. Neuropharmacology 2023 Feb 1;223:109351. Cheng YJ, Lin CH*, Lane HY*
The identification of a potential plasma metabolite marker for Alzheimer’s disease by LC-MS untargeted metabolomics Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences. 2023 Mar 30;1222:123686. Lin CH, Lin YN, Chen CJ*, Lane HY*
The Associations between Cognitive Functions and TSNAX Genetic Variations in Patients with Schizophrenia. Pharmacology, Biochemistry and Behavior 2023 Apr 6;173554. Kuan-Yu Huang, Yu-Jhen Huang, Shaw-Ji Chen, Lin CH*, Lane HY*
Differential Relationships of NMDAR Hypofunction and Oxidative Stress with Cognitive Decline. Psychiatry Research 2023 Aug;326:115288. Lane HY, Wang SH, Lin CH*
Differential impacts of endogenous antioxidants on clinical symptoms and cognitive function in acute and chronic schizophrenia patients.
The International Journal of Neuropsychopharmacology 2023 Aug 29;26(8):576-583. Lin CH, Li TM, Huang YJ, Chen SJ, Lane HY*
Adjunctive transcranial direct current stimulation (tDCS) plus sodium benzoate for the treatment of early-phase Alzheimer's disease: A randomized, double-blind, placebo-controlled trial. Psychiatry Research 2023 Oct;328:115461. Lane HY, Wang SH, Lin CH*
Elucidating the Mechanisms of Sodium Benzoate in Alzheimer's Disease: Insights from Quantitative Proteomics Analysis of Serum Samples. The International Journal of Neuropsychopharmacology 2023 Dec 18;26(12):856-866. Lin CH, Liao HY, Lane HY, Chen CJ*
Inference of social cognition in schizophrenia patients with neurocognitive domains and neurocognitive tests using automated machine learning. Asian Journal of Psychiatry 2024 Jan;91:103866. Lin Eugene, Lin CH*, Lane HY*
Sodium benzoate: a novel multi-target pharmaceutical approach to rescue clozapine-resistant schizophrenia. Schizophrenia Research 2024 June;268:261-264. Lin CH, Lane HY*
Ramelteon protects against social defeat stress-associated abnormal behaviors. Pharmacology, Biochemistry and Behavior 2024 Jun 2:241:173794. Chen CJ, Yeh WL, Vichuda Charoensaensuk, Lin CJ, Yang LY, Xie SY, Lane HY, Lin CH, Wang YW, Tsai CF, Lu DY*
Sex- and dose-dependent catalase increase and its clinical impact in a benzoate dose-finding, randomized, double-blind, placebo-controlled trial for Alzheimer's disease. Pharmacology, Biochemistry and Behavior 2024 Oct:245:173885. Lane HY, Wang SH, Lin CH*
Increase in Luteinizing Hormone is Linked to Reduction in Depression in Patients with Dementia: Secondary Analysis of a Randomized Clinical Trial of Benzoate. Psychiatry and Clinical Neurosciences. 2025 Feb 20. Lin CH, Wang SH, Lane HY*
Interpretable machine learning to evaluate relationships between DAO/DAOA (pLG72) protein data and features in clinical assessments, functional outcome, and cognitive function in schizophrenia patients. Schizophrenia (Heidelb). 2025 Feb 22;11(1):27. Lin CH, Lin Eugene*, Lane HY*
Inverse dose-dependent effects of aripiprazole on sexual dysfunction and prolactin levels in patients with schizophrenia. Journal of Psychiatric Research 2025 Feb 27;184:112-117. Tzu-Hua Wu, Kah Kheng Goh, Yi-Hang Chiu, Chieh-Hsin Lin, Chun-Hsin Chen, Hsien-Yuan Lane, Mong-Liang Lu*